Amylyx Pharmaceuticals’ mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. We are pursuing commercialization of our product candidate, AMX0035, which we believe is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. We are actively pursuing regulatory approvals of AMX0035 for the treatment of ALS in Canada, the United States and Europe. We have recently initiated a Phase 3 clinical trial of AMX0035 for the treatment of ALS at clinical trial sites in the United States and Europe.